AAIPharma bulks up; Teva CEO Yanai to retire;

> AAIPharma is buying equipment and adding a filling line at one North Carolina facility, adding a second work shift at another, and building a 40,000-square-foot lab and technology center at its Wilmington headquarters site. Story | Story

> Teva Pharmaceutical president ($TEVA) and CEO Shlomo Yanai plans to retire in May 2012; Jeremy Levin, formerly with Bristol-Myers Squibb, is expected to succeed him. Teva release

> Athena Drug Delivery Solutions will develop, manufacture and commercialize AtorFen (fenofibrate-atorvastin fixed dose combination), an investigational cholesterol drug from Veloxis Pharmaceuticals, which will get 70% of revenues. News

> Micro Labs has ordered GEA Pharma Systems' Flexstream process technology for spray granulation and pellet coating. Item

> Alarmed over the domestic pharma companies being acquired by multinational Big Pharmas, Indian officials have done away with automatic approvals for foreign direct investment. Report

> A new three-layer heat-sealed plastic film from BASF will protect the active ingredient Kollidon against contact with oxygen, allowing a lower peroxide level of the material. News

> Actavis has named Agility Spain to transport 300 pallets of drugs from a Malta production site to 15 European countries for generics launches. Item

> For sale: A well-established pharmaceutical manufacturing and marketing company available for immediate majority equity acquisition or outright sale in India. Listing

Suggested Articles

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.

A warning letter says Chinese API maker Yibin Lihao Bio-technical was found lying to the FDA about manufacturing unapproved heparin.

It took four tries over four years, but Perrigo has finally gotten FDA approval of its generic of Teva’s tricky-to-make ProAir HFA asthma inhaler.